Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy

Identification of EGFR kinase domain mutations among lung cancer patients in China: implication... Lung cancer is one of the leading causes of death with one of the lowest survival rates. However, a subset of lung cancer patients who are of Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib and erlotinib. While EGFR mutation profiles have been reported from Japan, South Korea, and Taiwan, there is no such report from mainland of China where the largest pool of patients reside. In this report, we identified ten somatic mutations from a total of 41 lung cancer patients in China. Among them, seven mutations were found in 17 adenocarcinomas. In contrast to previous reports, eight of these mutations are deletions in exon 19 and two of these deletions are homozygous. These results suggest that a large portion of Chinese adenocarcinoma patients could benefit from gefitinib or erlotinib. This unique mutation profile provides a rationale to develop the next generation of EGFR inhibitors more suitable for the Chinese population. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cell Research Springer Journals

Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy

Loading next page...
 
/lp/springer-journals/identification-of-egfr-kinase-domain-mutations-among-lung-cancer-rzOvXThurp

References (14)

Publisher
Springer Journals
Copyright
Copyright © 2005 by Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
Subject
Life Sciences; Life Sciences, general; Cell Biology
ISSN
1001-0602
eISSN
1748-7838
DOI
10.1038/sj.cr.7290289
Publisher site
See Article on Publisher Site

Abstract

Lung cancer is one of the leading causes of death with one of the lowest survival rates. However, a subset of lung cancer patients who are of Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib and erlotinib. While EGFR mutation profiles have been reported from Japan, South Korea, and Taiwan, there is no such report from mainland of China where the largest pool of patients reside. In this report, we identified ten somatic mutations from a total of 41 lung cancer patients in China. Among them, seven mutations were found in 17 adenocarcinomas. In contrast to previous reports, eight of these mutations are deletions in exon 19 and two of these deletions are homozygous. These results suggest that a large portion of Chinese adenocarcinoma patients could benefit from gefitinib or erlotinib. This unique mutation profile provides a rationale to develop the next generation of EGFR inhibitors more suitable for the Chinese population.

Journal

Cell ResearchSpringer Journals

Published: Mar 1, 2005

There are no references for this article.